Valeant Pharmaceuticals International Will Sweeten $46 Billion Allergan Inc. Bid

Published: May 14, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Valeant Pharmaceuticals says it will upgrade its unsolicited bid to buy specialty drugmaker Allergan for nearly $46 billion, and it wants to tell Allergan shareholders why it offers the better deal. The Canadian drugmaker says it will host a webcast later this month to explain why the cash-and-stock offer it announced last month is better than Allergan's plan to continue running as a stand-alone company. Valent says it will improve its offer to show its commitment to getting a deal done.

Help employers find you! Check out all the jobs and post your resume.

Back to news